Chung Wu Investment Group LLC Acquires Shares of 1,000 Natera, Inc. $NTRA

Chung Wu Investment Group LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 1,000 shares of the medical research company’s stock, valued at approximately $169,000.

Several other hedge funds have also recently made changes to their positions in the business. Guided Capital Wealth Management LLC boosted its position in shares of Natera by 0.5% during the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock valued at $2,219,000 after buying an additional 66 shares during the period. Wedmont Private Capital boosted its holdings in shares of Natera by 4.9% in the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock valued at $256,000 after buying an additional 74 shares in the last quarter. Compound Planning Inc. grew its position in shares of Natera by 4.2% in the 1st quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company’s stock worth $271,000 after buying an additional 78 shares during the last quarter. QRG Capital Management Inc. raised its stake in shares of Natera by 1.5% during the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock worth $766,000 after acquiring an additional 81 shares in the last quarter. Finally, Earned Wealth Advisors LLC lifted its position in Natera by 5.0% during the first quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 82 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Performance

Shares of Natera stock opened at $167.35 on Monday. The firm has a 50-day simple moving average of $161.17 and a two-hundred day simple moving average of $156.66. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $183.00. The company has a market cap of $22.97 billion, a P/E ratio of -87.62 and a beta of 1.74.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The business had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. Natera’s revenue was up 32.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

NTRA has been the topic of several analyst reports. Evercore ISI raised shares of Natera to a “strong-buy” rating and set a $170.00 price target on the stock in a report on Monday, July 28th. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company initiated coverage on Natera in a research report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 target price on the stock. Stephens reiterated an “overweight” rating and issued a $183.00 price target on shares of Natera in a research note on Friday, August 15th. Finally, Piper Sandler restated an “overweight” rating and set a $220.00 price target (up previously from $210.00) on shares of Natera in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $192.88.

Insiders Place Their Bets

In other news, Director Rowan E. Chapman sold 2,750 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the transaction, the director directly owned 6,015 shares of the company’s stock, valued at $1,004,444.85. This represents a 31.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider John Fesko sold 678 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the transaction, the insider owned 152,747 shares in the company, valued at $23,746,048.62. This trade represents a 0.44% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,464 shares of company stock valued at $10,963,125. 5.63% of the stock is owned by insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.